In this study, we firstly evaluated the antitumor effect of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001 (everolimus), in a panel of endometrial cancer cell lines. This evidence concerns the gene PIK3CA and endometrial cancer.